Disrupted access and diverging pathways to sexual health services during COVID-19: insights from the PrEP Impact Trial in England
7 affiliations
- 1UK Health Security Agency, Blood Safety, Hepatitis, STI & HIV (BSHSH) Division, 61 Colindale Avenue, London, NW9 5EQ UK
- 2Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
- 3The National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted, Infections at University College London, London, UK
- 4Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, UK
- 5Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK
- 6North Cumbria Integrated Care NHS Foundation Trust, Penrith, UK
- 7University College London, London, UK
Abstract
Background: Using data from the HIV pre-exposure prophylaxis (PrEP) Impact trial, an implementation trial of PrEP across sexual health services to inform routine PrEP commissioning in England, we examined sexual health service use and PrEP need during UK COVID-19 social restrictions (March-November 2020) to assess the pandemic’s impact on PrEP delivery in England. This is the first analysis extending trial data beyond February 2020.
Methods: We collated monthly aggregate data from 157 PrEP Impact Trial clinics in England (October 2017–November 2020), focusing on gay, bisexual, and other men who have sex with men (MSM). For trial participants and non-trial attendees (NTA), we examined trends in service use, STI/HIV test positivity, PrEP need, and prescriptions (30, 60, 90, ≥ 120 tablets). We also assessed changes in the enrolment patterns of key subgroups (aged 16–24, ethnic minority background, and bacterial STI history) over time. COVID-19 restrictions were defined as March–July and September–November 2020.
Results: Attendances markedly decreased between February and April 2020 (-34% for trial participants; -78% for NTA). By July 2020, trial participant attendances had nearly returned to pre-lockdown levels, while NTA attendances remained more than 50% lower than in January. HIV and STI test positivity increased more among NTA than trial attendees during restrictions, reaching 0.95% [95% CI 0.51–1.63] and 18.9% [95% CI 17.0-20.9] respectively. This suggests triage towards higher risk individuals but also highlights likely unmet need among others. The proportion of clinic attendees with PrEP need also increased during the pandemic, and short-lived increases to longer term prescriptions were observed. Demographic shifts during restrictions showed decreased in-person enrolment among younger people and increased representation of ethnic minority groups.
Conclusions: Structured PrEP delivery preserved access among trial participants during COVID-19-related disruptions, but non-trial attendees, despite persistent risk, faced greater barriers and slower recovery. These disparities underscore the need for resilient, flexible delivery models that can sustain HIV prevention in periods of major service disruptions. With continued PrEP scale-up, addressing equity gaps for those outside established care pathways will be essential to prevent widening disparities and ensure the success of HIV prevention efforts.
Trial registration: The study is registered with ClinicalTrials.gov (Prospective, non-interventional trial NCT03253757; registered 06/16/2017).
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14044-5.
Related
- Mixed-methods evaluation of a rights-based intervention to reduce long-term segregation in mental health services: the HOPE(S) National Programme in England.
- Inequality in secondary fracture prevention supports prioritisation of fracture liaison services in coastal health plans in England and Wales
- Psychological therapy for children and young people with a diagnosis of autism or intellectual disabilities in mainstream child and adolescent mental health services: a cross-sectional survey of clinicians’ perspectives in England
- Factors associated with the quality of urban geriatric healthcare services empowered by large language models and improvement pathways: a theoretical framework and cross-sectional study
- Perinatal Bisphenol S Exposure Induces Hepatotoxicity in Female Rat Offspring: Insights into Disrupted Hepatic Cholesterol Homeostasis.
BibTeX
@article{ogaz2026disrupted,
title = {{Disrupted access and diverging pathways to sexual health services during COVID-19: insights from the PrEP Impact Trial in England}},
author = {Dana Ogaz and Chiara Chiavenna and Holly D. Mitchell and Andrea Cartier and Rainer Golombek and Andre Charlett and Sajjida Jaffer and Victor Diamente and Hamish Mohammed and Elizabeth Carlin and Patricia Williams and Matt Phillips and O. Noel Gill and John Saunders and Ann K. Sullivan},
journal = {BMC Infectious Diseases},
year = {2026},
month = jul,
doi = {10.1186/s12879-026-14044-5},
url = {https://doi.org/10.1186/s12879-026-14044-5},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Disrupted access and diverging pathways to sexual health services during COVID-19: insights from the PrEP Impact Trial in England
AU - Dana Ogaz
AU - Chiara Chiavenna
AU - Holly D. Mitchell
AU - Andrea Cartier
AU - Rainer Golombek
AU - Andre Charlett
AU - Sajjida Jaffer
AU - Victor Diamente
AU - Hamish Mohammed
AU - Elizabeth Carlin
AU - Patricia Williams
AU - Matt Phillips
AU - O. Noel Gill
AU - John Saunders
AU - Ann K. Sullivan
PY - 2026
DA - 2026/07/28
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-14044-5
UR - https://doi.org/10.1186/s12879-026-14044-5
AB - Background: Using data from the HIV pre-exposure prophylaxis (PrEP) Impact trial, an implementation trial of PrEP across sexual health services to inform routine PrEP commissioning in England, we examined sexual health service use and PrEP need during UK COVID-19 social restrictions (March-November 2020) to assess the pandemic’s impact on PrEP delivery in England. This is the first analysis extending trial data beyond February 2020. Methods: We collated monthly aggregate data from 157 PrEP Impact Trial clinics in England (October 2017–November 2020), focusing on gay, bisexual, and other men who have sex with men (MSM). For trial participants and non-trial attendees (NTA), we examined trends in service use, STI/HIV test positivity, PrEP need, and prescriptions (30, 60, 90, ≥ 120 tablets). We also assessed changes in the enrolment patterns of key subgroups (aged 16–24, ethnic minority background, and bacterial STI history) over time. COVID-19 restrictions were defined as March–July and September–November 2020. Results: Attendances markedly decreased between February and April 2020 (-34% for trial participants; -78% for NTA). By July 2020, trial participant attendances had nearly returned to pre-lockdown levels, while NTA attendances remained more than 50% lower than in January. HIV and STI test positivity increased more among NTA than trial attendees during restrictions, reaching 0.95% [95% CI 0.51–1.63] and 18.9% [95% CI 17.0-20.9] respectively. This suggests triage towards higher risk individuals but also highlights likely unmet need among others. The proportion of clinic attendees with PrEP need also increased during the pandemic, and short-lived increases to longer term prescriptions were observed. Demographic shifts during restrictions showed decreased in-person enrolment among younger people and increased representation of ethnic minority groups. Conclusions: Structured PrEP delivery preserved access among trial participants during COVID-19-related disruptions, but non-trial attendees, despite persistent risk, faced greater barriers and slower recovery. These disparities underscore the need for resilient, flexible delivery models that can sustain HIV prevention in periods of major service disruptions. With continued PrEP scale-up, addressing equity gaps for those outside established care pathways will be essential to prevent widening disparities and ensure the success of HIV prevention efforts. Trial registration: The study is registered with ClinicalTrials.gov (Prospective, non-interventional trial NCT03253757; registered 06/16/2017). Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14044-5.
SN - 1471-2334
ER -